CA3013532C - Liraglutide in cardiovascular conditions - Google Patents

Liraglutide in cardiovascular conditions Download PDF

Info

Publication number
CA3013532C
CA3013532C CA3013532A CA3013532A CA3013532C CA 3013532 C CA3013532 C CA 3013532C CA 3013532 A CA3013532 A CA 3013532A CA 3013532 A CA3013532 A CA 3013532A CA 3013532 C CA3013532 C CA 3013532C
Authority
CA
Canada
Prior art keywords
subject
placebo
liraglutide
mace
death
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA3013532A
Other languages
English (en)
French (fr)
Other versions
CA3013532A1 (en
Inventor
Soren Rasmussen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59723004&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3013532(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CA3013532A1 publication Critical patent/CA3013532A1/en
Application granted granted Critical
Publication of CA3013532C publication Critical patent/CA3013532C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
CA3013532A 2016-03-04 2017-03-03 Liraglutide in cardiovascular conditions Expired - Fee Related CA3013532C (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP16158739.9 2016-03-04
EP16158739 2016-03-04
EP16173917 2016-06-10
EP16173917.2 2016-06-10
EP16001329 2016-06-13
EP16001329.8 2016-06-13
US15/401651 2017-01-09
US15/401,651 US9968659B2 (en) 2016-03-04 2017-01-09 Liraglutide in cardiovascular conditions
PCT/EP2017/054990 WO2017149112A1 (en) 2016-03-04 2017-03-03 Liraglutide in cardiovascular conditions

Publications (2)

Publication Number Publication Date
CA3013532A1 CA3013532A1 (en) 2017-09-08
CA3013532C true CA3013532C (en) 2019-07-23

Family

ID=59723004

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3013532A Expired - Fee Related CA3013532C (en) 2016-03-04 2017-03-03 Liraglutide in cardiovascular conditions

Country Status (24)

Country Link
US (2) US9968659B2 (enExample)
EP (1) EP3423082B1 (enExample)
JP (1) JP6940512B2 (enExample)
KR (1) KR102417455B1 (enExample)
CN (2) CN108778317A (enExample)
AU (2) AU2017225841A1 (enExample)
BR (1) BR112018067344A2 (enExample)
CA (1) CA3013532C (enExample)
CL (1) CL2018002515A1 (enExample)
DK (1) DK3423082T5 (enExample)
ES (1) ES2893755T3 (enExample)
HR (1) HRP20211492T1 (enExample)
HU (1) HUE055844T2 (enExample)
IL (1) IL261169B (enExample)
MA (1) MA43704A (enExample)
MX (1) MX394179B (enExample)
MY (1) MY195657A (enExample)
PH (1) PH12018501844B1 (enExample)
PL (1) PL3423082T3 (enExample)
RS (1) RS62501B1 (enExample)
RU (1) RU2745604C2 (enExample)
SI (1) SI3423082T1 (enExample)
WO (1) WO2017149112A1 (enExample)
ZA (1) ZA201805538B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions
PL3448416T3 (pl) 2016-04-28 2022-11-07 Novo Nordisk A/S Semaglutyd w schorzeniach sercowo-naczyniowych
CA3056663C (en) 2019-04-05 2022-10-18 Jeffrey S. RIESMEYER Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus
EP4262873A4 (en) * 2020-12-16 2024-12-11 The Chinese University of Hong Kong A method for reversing aging brain functional decline

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5808203A (en) 1997-05-12 1998-09-15 Medrad, Inc. Fluid pressure measurement devices
EP1494704A1 (en) * 2002-04-04 2005-01-12 Novo Nordisk A/S Glp-1 agonist and cardiovascular complications
KR101243648B1 (ko) * 2003-11-20 2013-03-14 노보 노르디스크 에이/에스 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
CN101056650A (zh) * 2004-11-12 2007-10-17 诺和诺德公司 促胰岛素肽的稳定制剂
EP2190872B1 (en) * 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
KR20110135411A (ko) 2009-03-27 2011-12-16 브리스톨-마이어스 스큅 컴퍼니 Ｄｐｐ-ｉｖ 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법
EP2566502A4 (en) 2010-05-04 2013-10-09 Glaxosmithkline Llc METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION
PH12012502524A1 (en) 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
EP2854812A1 (en) 2012-05-24 2015-04-08 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
CN103893744B (zh) * 2012-12-24 2017-12-19 杭州九源基因工程有限公司 一种治疗糖尿病的药物制剂及其制备方法
JP2016510795A (ja) 2013-03-15 2016-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用
KR102238860B1 (ko) 2013-06-14 2021-04-12 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 및 이의 합병증의 치료를 위한 dpp-4 억제제
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions

Also Published As

Publication number Publication date
US20180236038A1 (en) 2018-08-23
DK3423082T3 (da) 2021-10-11
JP2019507174A (ja) 2019-03-14
EP3423082A1 (en) 2019-01-09
HRP20211492T1 (hr) 2021-12-24
EP3423082B1 (en) 2021-08-04
HUE055844T2 (hu) 2021-12-28
ZA201805538B (en) 2020-05-27
MX2018010097A (es) 2018-11-09
US20170252408A1 (en) 2017-09-07
CN108778317A (zh) 2018-11-09
RU2745604C2 (ru) 2021-03-29
SI3423082T1 (sl) 2021-10-29
PL3423082T3 (pl) 2021-12-27
MY195657A (en) 2023-02-03
CL2018002515A1 (es) 2018-11-09
US9968659B2 (en) 2018-05-15
IL261169B (en) 2019-11-28
KR102417455B1 (ko) 2022-07-06
PH12018501844A1 (en) 2019-05-15
ES2893755T3 (es) 2022-02-10
AU2024201937A1 (en) 2024-04-11
BR112018067344A2 (pt) 2019-01-08
KR20180114168A (ko) 2018-10-17
CA3013532A1 (en) 2017-09-08
WO2017149112A1 (en) 2017-09-08
RU2018134061A (ru) 2020-04-06
CN116327897A (zh) 2023-06-27
AU2017225841A1 (en) 2018-08-23
PH12018501844B1 (en) 2023-03-17
MA43704A (fr) 2021-04-14
IL261169A (en) 2018-10-31
DK3423082T5 (da) 2023-02-06
JP6940512B2 (ja) 2021-09-29
RS62501B1 (sr) 2021-11-30
MX394179B (es) 2025-03-24
RU2018134061A3 (enExample) 2020-07-15

Similar Documents

Publication Publication Date Title
US20250262281A1 (en) Semaglutide in Cardiovascular Conditions
AU2024201937A1 (en) Liraglutide in cardiovascular conditions
US12233114B2 (en) Method for treating diabetes
US11673933B2 (en) Method for using insulin degludec for the improvement of glycemic control and reduction of acute and long-term diabetes complications
US20190091295A1 (en) Liraglutide in Renal Conditions
US20190070266A1 (en) Liraglutide in Diabetic Foot Ulcer
HK1259166A1 (en) Liraglutide in cardiovascular conditions
HK1259166B (en) Liraglutide in cardiovascular conditions
WO2018096164A1 (en) Insulin degludec for treating diabetes
BR122025010585A2 (pt) Uso de semaglutida para reduzir o risco de um evento cardiovascular adverso maior (mace) em indivíduos com diabetes mellitus tipo 2 e alto risco cardiovascular

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180802

MKLA Lapsed

Effective date: 20210903

MKLA Lapsed

Effective date: 20200303